A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
Publications | Flatiron Health
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial - The Lancet Oncology
Bavencio HCP UC Efficacy
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
PLOS ONE: Human Glial-Restricted Progenitor Transplantation into Cervical Spinal Cord of the SOD1G93A Mouse Model of ALS
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
Survival (time to event) Outcomes | Health Knowledge
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Articles Archives - Page 2 of 10 - GNS
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis | Prostate Cancer and Prostatic Diseases
LENVIMA® (lenvatinib) HCP Website | Clinical Study Design
Secondary outcome measure. The median follow-up of 15.7 months. The... | Download Scientific Diagram
Bavencio HCP UC Efficacy
Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports
JCI Insight - A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia
Drug Trials Snapshot: LONSURF | FDA
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
LENVIMA® (lenvatinib) HCP Website | Overall Survival (OS)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Evaluating eligibility criteria of oncology trials using real-world data and AI | Nature
JCI Insight - A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Prioritizing Patient Preferences for Ovarian Cancer Treatment | Duke Health Referring Physicians
Event-free and overall survival of all eligible patients on the study. | Download Scientific Diagram
